By Katie Reid
ZURICH, Jan 31 (Reuters) – Novartis AG’s (NOVN.VX) vaccine against meningococcal disease, a cause of potentially deadly meningitis, failed to get U.S. backing for use in infants between two months and 12 months of age, the Swiss drugmaker said.
The news comes as a setback for Novartis’s meningitis franchise as its Vaccines and Diagnostics unit looks to its meningitis vaccines, as well as its strong pipeline, to reduce dependency on sales from pandemic vaccines. [ID:nLDE70Q11K]
Leave a Reply